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found in the ampliﬁed cell lines. This ampliﬁcation confers sensitiv-
ity of NSCLC to inhibitors of the tyrosine kinase activity of c-Met. To 
further determine the molecular characteristics of cell lines carrying 
c-Met ampliﬁcation, we investigated the levels of downstream effectors 
of c-Met, such as phospho paxillin, phospho-extracellular signal-
regulated kinase and phospho-S6 proteins. Interestingly, S6 kinase a 
serine-threonine kinase whose activation is thought to regulate a wide 
array of cellular processes involved in the mitogenic response including 
protein synthesis, translation of speciﬁc mRNA species, and cell cycle 
progression from G1 to S phase was more frequently activated in cell 
lines with gene ampliﬁcation of c-Met than in their wild-type counter-
parts. c- Met ampliﬁcation may thus identify a subset of lung cancers 
that are uniquely altered signaling which potentially sensitive to c-Met 
inhibition.
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Background: Lung cancer still remains one of the leading causes of 
all cancer related deaths. They can be divided into two major types, 
non small cell (NSCLC) and small cell (SCLC) lung cancers. Amongst 
the two, prognosis in patients with NSCLC is better compared to those 
with SCLC, however the overall survival rate is still very low (17%). 
A plethora of molecular changes due to various genomic alterations are 
known to contribute to the development and spread of lung cancers, for 
instance mutations in p53, RB, Ras, several receptor and non-receptor 
tyrosine kinases are known to contribute to the variety of phenotypes 
seen in lung cancer. One of the long term goals of our lab is to map and 
study the biological signiﬁcance of loss and gain of function mutations 
in various signaling molecules in lung cancer; with the idea of develop-
ing novel therapeutics. In this regard, we examined the role of Pax 
transcription factors in lung cancer. To date, the Pax family consists 
of nine members that are all characterized by the presence of a paired 
domain. They are indispensable for various developmental processes 
and several of them are known to play a signiﬁcant role in the develop-
ment of various cancers. In this initial study, we used a panel of both 
NSCLC and SCLC cell lines to determine the relative levels of various 
Pax proteins. 
Methods: Whole cell lysates from a panel of NSCLC and SCLC cell 
lines were prepared using RIPA Buffer. Equivalent amount cell lysates 
proteins were separated by SDS-PAGE and subjected to immunoblot-
ting using various commercially available anti-Pax antibodies. 
Speciﬁc Pax knockdown cells were also generated by transfecting com-
mercially available siRNA. The loss of the particular Pax expression 
was determined using immunoblotting procedures.
Results: We detected signiﬁcant expression of Pax8 in NSCLC and 
Pax5 in SCLC cell lines. In addition we could detect BCL2 but not 
BCL-XL, especially in the SCLC cell lysates. Since Pax3 is a known 
direct transcriptional activator of c-Met, a receptor tyrosine kinase that 
is known to play a signiﬁcant role in cancer metastasis, we therefore 
determined the protein expression levels of c-Met in the above cell 
lines. In general, in most of the cell lines where Pax expression was de-
tected, we also detected comparable levels of c-MET. We are currently 
determining how the Pax factors can regulate biological and biochemi-
cal processes in lung cancer.
Conclusions: Differential expression of Pax8 in NSCLC and Pax5 in 
SCLC can be further tested as biomarkers to characterize lung tumor 
tissue biopsies. This differential expression can be combined with other 
biomarkers to help distinguish between SCLC, NSCLC, and other 
tumors.
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Propose: Authors are to investigate DNA repair mechanisms 
involved in DNA damage induced by cis-Diammineplatinum 
dichloride(cisplatin), which is widely used for treatment of NSCLC. 
We also studied relevance of IGF-1 system in DNA repair mechanisms.
Methods: The effect on non-small cell lung cancer (NSCLC) cell 
line NCI-H1299 and NCI-H460 proliferation by IGF-1 and cisplatin 
treatment was measured by MTT assay. Changes of molecular system 
consisting HRR and NEJH were evaluated by immunoblotting and im-
munocytochemistry. Comet assay was applied to analyze inﬂuence of 
IGF-1 on DNA damage repair.
Results: 
1. Cisplatin treatment resulted in inhibition of cell proliferation in a 
dose dependent manner. IC50 and IC80 are about 33.3 uM and 9.1 
uM in H1299 and 33.7uM and 8uM in H460 cells. 50 ng/ml IGF-1 
treatment on each cells recovered about 20% of cell proliferation 
repressed by cisplatin.
2. Immunocytochemical study showed cisplatin treatment induced 
activation of gamma H2AX, and addition of 50 ng/mL IGF-1 po-
tentated its activation. Nuclear translocation of ATM and IRS-1 was 
promoted by cisplatin treatment, but was suppressed by IGF-1. On 
the other hand, translocation of ATR was enhanced by cisplatin and 
facilitated by IGF-1 treatment. 
3. Phsphorylation of ATM induced by cisplatin was conﬁrmed by 
immunoblotting, but not with IGF-1. Whereas IGF-1 induced ATR 
activation, and promoted gamma H2AX formation.
4. Reduced cisplatin induced DNA damage could verify IGF-1 effect 
with comet assay.
Conclusions: Activation of ATR pathway by IGF-1 might be primary 
recovery mechanism of cisplatin induced DNA damage.
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Introduction: EGFR-TIKs showed about twenty percent of response 
rate in refractory non-small cell lung cancer. Clinical trials of cytotoxic 
drugs and EGFR-TIKs failed to show improved survival compared 
to platinum based doublets. An antagonism between EGFR-TKIs and 
cytotoxic chemotherapy drugs was raised as a possible explanation for 
the negative results. 
Materials and Methods: The antiproliferative effects and cell cycle 
distributions after treatments with EGFR-TKIs(geﬁtinib and erlotinib) 
and cytotoxic drugs(Docetaxel, Paclitaxel, Gemcitabine) were studied 
using a cell line(NCI-H1975, adenocarcinoma of lung) harboring 
T790M mutation in exon 20 of EGFR gene. The cell viability assay and 
cell cycle analysis were performed with MTT assay and ﬂow cytome-
try. EGFR-TKIs and cytotoxic drugs were treated in different sequenc-
es to observe sequence dependent effect. Calcusyn software(Biosoft, 
Cambridge, UK) was used to calculate combination index(CI). 
Results: Various combinations of cytotoxic drugs and EGFR-TKIs 
showed different antiproliferative effects on NCI-H1975 cell line. 
Antagonisms(CI>1) were observed when EGFR-TKIs were treated 
before cytotoxic drugs(EC sequence), while synergisms(CI<1) were 
observed when cytotoxic drugs were pre-treated before EGFR-
TKIs(CE sequence). Treatment in EC sequence arrested the cells in 
G0/G1 phase and decreased the apoptotic fraction. However, treatment 
in CE sequence arrested the cells in G2/M phase and higher fractions of 
apoptotic cell death were observed. 
Conclusion: To combine EGFR-TKIs and cytotoxic drugs, sequence 
dependent anti-proliferative effects should be considered. 
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Galectin-9 is a member of the β-galactoside-binding galectin family 
proteins associated with diverse biological processes, such as apopto-
sis, cell aggregation and eosinophilic chemoattraction. Some reports 
described that galectin-9 was a possible prognostic factor in breast 
cancer and melanoma.
We have found stromal spindle cells are occasionally positive for ga-
lectin-9 in our previous study (data not shown). Herein, we investigated 
its clinicopathological signiﬁcance using lung cancer tissue microarray 
(TMA). We immunohistochemically examined the expression of galec-
tin-9 in lung cancer using TMA containing samples from 400 surgical 
cases. Cancerous stroma was microscopically recognized in 183 cases 
(109 adenocarcinoma, 70 squamous cell carcinoma and 4 adenosqua-
mous cell carcinoma cases). 
Total of 24.6 % cases (45/183) showed galectin-9 expression in stromal 
spindle cells. We examined the survival statistical signiﬁcance of ga-
lectin-9 using the log-rank test, and Kaplan-Meier curves were plotted. 
Positive immunohistochemical staining with galectin-9 was associated 
with favorer survival for patients with lung cancer (5-year survival of 
59.2% versus 31.3% p=0.0206).
Conclusion: Our data indicates that galectin-9 in cancerous stroma can 
be a better prognostic biomarker in lung cancer.
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Podoplanin is a mucin-type glycoprotein and a noble lymphatic endo-
thelial marker. Immunohistochemical staining against podoplanin is 
currently a useful tool to detect lymphatic involvement of cancer cells, 
and is widely used in a routine pathological diagnosis. By observation 
of daily cases, we have noticed stromal spindle cells are occasionally 
positive for podoplanin. To conﬁrm its presence and to investigate its 
clinical signiﬁcance, we immunohistochemically examined podoplanin 
expression using several monoclonal antibodies and tissue microarrays.
We found that stromal podoplanin expression in adenocarcinoma was 
signiﬁcantly associated with poorer prognosis (p<0.001). The prognos-
tic signiﬁcance was still high after adjustment with stage, gender, age, 
and histological differentiation (p<0.001). The expression was associ-
ated with differentiation and tended to associate with nodal metastasis. 
Also we immunohistochemically examined with 14 common cancer 
types and found that podoplanin expression was signiﬁcantly associated 
with nodal metastasis (p<.01). Our data indicates that podoplanin ex-
pression in cancerous stromal cells may play a critical role in lymphatic 
invasion of cancer cells to determine patients’ survival. 
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Background: Apoptosome pathway dysfunction in tumor cells may 
account for their apoptosis resistance and there is evidence that sur-
vivin (Sur) and some its alternative splice variants may be involved in 
regulation of this cell death pathway in malignant tumors. In this work, 
we studied the expression of transcripts encoding Sur and its splice 
variants Sur-3B, Sur-2B and Sur-ΔEx3 in non-small cell lung carci-
noma (NSCLC) tissues and lung parenchyma from surgically treated 
patients and examined the impact of survivin gene promoter genotype 
at nucleotide -31 and of the smoking status of NSCLC patients on the 
expression level of the indicated Sur transcript variants. 
Methods: The expression of mRNAs encoding Sur, Sur-3B, Sur-2B 
and Sur-ΔEx3 was quantitated by real time RT-PCR using transcript-
speciﬁc oligonucleotide primers and TaqMan ﬂuorogenic probes, and 
an input of total RNA isolated from NSCLC and lung tissues. The 
expression of Sur transcript variants was normalized against the expres-
sion of β-actin mRNA. Genotyping of the survivin gene promoter in 
NSCLC and lung tissues was performed by PCR ampliﬁcation and 
DNA sequencing of the puriﬁed PCR product with nested primers. 
